Mangalam Drugs Defaults On Loan Repayments To Bank Of Baroda And Bank Of Maharashtra

Mangalam Drugs and Organics Ltd has officially disclosed a default on its loan repayments to two major public sector lenders—Bank of Baroda and Bank of Maharashtra. The announcement was made in compliance with SEBI’s Regulation 30 disclosure norms and reflects mounting financial strain within the pharmaceutical manufacturing segment.

The company, which specializes in active pharmaceutical ingredients (APIs) and intermediates, has not provided detailed figures on the defaulted amount but confirmed the lapse in servicing scheduled debt obligations. The development comes amid broader challenges in the pharma sector, including pricing pressures, regulatory costs, and working capital constraints.

Key developments include:  

• The default pertains to term loans and working capital borrowings from Bank of Baroda and Bank of Maharashtra.
• The company has yet to issue a formal recovery or restructuring plan, raising investor concerns over future solvency.
• Mangalam Drugs had previously undergone credit rating revisions, with Crisil Ratings reaffirming its long-term debt as under watch.
• The company’s financial disclosures indicate rising debt levels and pressure on operating margins in recent quarters.
• Regulatory filings suggest the default may impact future borrowing capacity and trigger lender-led corrective action.

Sources: BSE Corporate Filings, Crisil Ratings Disclosure (January 2025), Mangalam Drugs and Organics Ltd Investor Updates.